<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250561</url>
  </required_header>
  <id_info>
    <org_study_id>CCS-06-001</org_study_id>
    <nct_id>NCT01250561</nct_id>
  </id_info>
  <brief_title>Reduction of Postherpetic Neuralgia in Herpes Zoster</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Clinical Studies, Texas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center for Clinical Studies, Texas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The addition of gabapentin therapy to standard antiviral treatment with valacyclovir in acute
      herpes zoster patients will decrease the incidence of post-herpetic neuralgia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with zoster pain at 6 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with zoster pain at 4 months</measure>
  </secondary_outcome>
  <enrollment type="Actual">133</enrollment>
  <condition>Herpes Zoster</condition>
  <condition>Post-herpetic Neuralgia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>valacyclovir 1000mg three-times daily x 7 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients of 50 years of age and older.

          -  Patients with a clinical diagnosis of uncomplicated herpes zoster presenting within
             the first 72 hours of vesicles.

          -  Patients who are willing and able to comply with the requirements of the study.

          -  Patients who are willing and able to give written informed consent.

          -  Average pain score pre-therapy greater or equal than 4 on 10-point Likert scale.

        Exclusion Criteria:

          -  Sexually-active women of childbearing potential, including postmenopausal women less
             than 1 year since last menses, not employing adequate contraception (approved oral
             contraceptive, intrauterine device, barrier methods or total abstinence).

          -  Pregnant females and nursing mothers.

          -  Patients with immune dysfunction including congenital immune deficiency, active
             malignancy of any type, collagen vascular diseases, organ or bone marrow
             transplantations, known infection with HIV or severe atopic dermatitis.

          -  Patients who have received cytotoxic drugs or immunosuppressive therapy (e.g., chronic
             systemic corticosteroids) within the previous 3 months.

          -  Patients with evidence of cutaneous or visceral dissemination of herpes zoster
             infection (cutaneous dissemination is defined as &gt; 20 discrete lesions outside
             adjacent dermatomes).

          -  Patients who have received systemic anti-VZV medications or immunomodulatory
             medications (including interferon) within the previous 4 weeks.

          -  Patients currently receiving probenecid.

          -  Patients with impaired renal function: calculated creatinine clearance of &lt;30 mL/min
             using Cockcroft and Gault formula.

          -  Patients with abnormal liver function (alanine transaminase (ALT) or
             aspartate;transaminase (AST) levels greater than five times the upper limit of the
             normal range).

          -  Patients with a history of intolerance or hypersensitivity to acyclovir, penciclovir,
             valacyclovir, famciclovir or gabapentin.

          -  Patients currently receiving therapy with gabapentin or tricyclic antidepressants.

          -  Patients with clinical evidence of ocular involvement of herpes zoster. Patients with
             herpes zoster of the ophthalmic branch of the trigeminal nerve without evidence of
             ocular involvement will be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Tyring, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Clinical Studies</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2010</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Stephen Tyring</name_title>
    <organization>Center for Clinical Studies</organization>
  </responsible_party>
  <keyword>gabapentin</keyword>
  <keyword>valacyclovir</keyword>
  <keyword>phn</keyword>
  <keyword>shingles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Neuralgia, Postherpetic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

